Specialties
David D. Aufhauser, MD
Assistant Professor
- Division of Transplantation
aufhauser@surgery.wisc.edu
(608) 265-6471
H4/752 Clinical Science Center
600 Highland Ave
Madison, WI 53792
Education
- MD, University of Pennsylvania, Philadelphia, PA
- Residency, Hospital of the University of the University of Pennsylvania, Philadelphia, PA
- Fellow, Abdominal Transplant Surgery, University of Wisconsin-Madison, Madison, WI
Clinical Specialties
Dr. Aufhauser is certified by the American Board of Surgery (ABS) and the American Society of Transplant Surgeons (ASTS). He specializes in liver, kidney and pancreas transplantation.
Dr. Aufhauser and Dr. Al-Adra performed a living liver transplant between two sisters to cure one of them of her rare disorder. Read more here.
Dr. Aufhauser provides a wide range of services including Pancreas Transplant, Liver Transplant, Kidney Transplant, Laparoscopic Donor Nephrectomy.
Research Interests
Dr. Aufhauser studies xenotransplantation with a focus on understanding and mitigating immune responses to xenoantigens. His long-term is to identify targets for genetic engineering and tailored immunosuppression that will facilitate clinical adaptation of xenotransplantation in humans to alleviate organ shortages.
Dr. Aufhauser received a one-year, $25,000 grant from the Association of Organ Procurement Organizations Foundation. Read more here.
Recent Publications
Dual Kidney Transplantation Offers Prolonged Graft Survival.
Fedorova E, Firmino SN, Foley D, Garonzik-Wang J, Kaufman D, Odorico J, Aufhauser D, Neidlinger NA, Thiessen C, Philip J, Collins KM, Mezrich J, Al-Adra D, Mandelbrot D, Astor BC, Parajuli S
Clin Transplant 2026 Feb; 40(2): e70481
[PubMed ID: 41674145]Importing pancreata for transplantation: a single-center experience across evolving allocation eras.
Tamburrini R, Hidalgo S, Leverson G, Kaufman DB, Neidlinger NA, Al-Adra DP, Aufhauser DD, Thiessen C, Mandelbrot D, Parajuli S, Odorico JS
Front Transplant 2025; 4: 1698617
[PubMed ID: 41488372]Rituximab-based antibody mediated rejection therapy modestly reduces Xenoreactive antibodies: Implications for pig-to-human xenotransplantation.
Yeh ST, Marshall NA, Lehman BP, Rubinstein CD, Shanmuganayagam D, Meudt JJ, Redfield RR, Hidalgo LG, Dominko T, Aufhauser DD
Transpl Immunol 2026 Feb; 94: 102343
[PubMed ID: 41401855]Outcomes of Patients With Localized Renal Cell Carcinoma on Immunosuppression Following Solid Organ Transplantation.
Shah PV, Abel EJ, Mezrich JD, Carey AZ, Taylor AK, Bregman A, Al-Adra D, Aufhauser D, Collins KM, Mandelbrot D, Lotan P, Lee FT, Hinshaw JL, Allen GO, Jarrard DF, Richards KA, Koehne EL, Risk MC, Shapiro DD
Urology 2025 Dec 11;
[PubMed ID: 41389849]Use of Cross-Sectional Imaging Body Composition Assessment to Predict Pancreas Transplant Outcomes.
Snook C, Ziemlewicz T, Leverson G, Parajuli S, Mandelbrot D, Al-Adra DP, Kaufman DB, Odorico JS, Aufhauser DD
Transpl Int 2025; 38: 15000
[PubMed ID: 41104385]